Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiake Xu

Showing results (371-380 of 401) with videos related to

Pageof 41
Sort By:
Biochemical Pharmacology|October 5, 2013
SC-514, a selective inhibitor of IKKβ attenuates RANKL-induced osteoclastogenesis and NF-κB activationQian Liu, Huafei Wu, Shek Man Chim, et al.
Scientific Reports|November 9, 2016
Nitidine chloride prevents OVX-induced bone loss via suppressing NFATc1-mediated osteoclast differentiationQian Liu, Tao Wang, Lin Zhou, et al.
Journal of Advanced Research|January 18, 2025
Transcriptional regulation of Rankl by Txnip-Ecd in aging and diabetic related osteoporosisXiankun Cao, Kexin Liu, Jinbo Yuan, et al.
Bioactive Materials|December 17, 2025
Designed bone-targeting ROS-responsive nanoplatform for precision glycolysis inhibition in postmenopausal osteoporosisQihang Wu, Jiansen Miao, Yu Chen, et al.
Journal of Cellular Physiology|September 23, 2020
A missense mutation sheds light on a novel structure-function relationship of RANKLHeng Qiu, An Qin, Taksum Cheng, et al.
Frontiers in Pharmacology|February 7, 2022
Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 PathwaysGang Wang, Chao Ma, Kai Chen, et al.
Molecular and Cellular Endocrinology|December 3, 2014
Triptolide inhibits osteoclast formation, bone resorption, RANKL-mediated NF-қB activation and titanium particle-induced osteolysis in a mouse modelJianbin Huang, Lin Zhou, Huafei Wu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 5, 2024
Bone-protective effects of neutralizing angiopoietin-like protein 4 monoclonal antibody in rheumatoid arthritisLiqing Ke, Qifei He, Jing Qu, et al.
Journal of Cellular Physiology|March 1, 2019
Daphnetin attenuates LPS-induced osteolysis and RANKL mediated osteoclastogenesis through suppression of ERK and NFATc1 pathwaysZuoxing Wu, Hailun Wu, Chen Li, et al.
Pharmacological Research|May 27, 2020
Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activationDelong Chen, Zhen Ye, Chao Wang, et al.
Pageof 41

Showing results (371-380 of 401) with videos related to

Sort By:
Pageof 41
Biochemical Pharmacology|October 5, 2013
SC-514, a selective inhibitor of IKKβ attenuates RANKL-induced osteoclastogenesis and NF-κB activationQian Liu, Huafei Wu, Shek Man Chim, et al.
Scientific Reports|November 9, 2016
Nitidine chloride prevents OVX-induced bone loss via suppressing NFATc1-mediated osteoclast differentiationQian Liu, Tao Wang, Lin Zhou, et al.
Journal of Advanced Research|January 18, 2025
Transcriptional regulation of Rankl by Txnip-Ecd in aging and diabetic related osteoporosisXiankun Cao, Kexin Liu, Jinbo Yuan, et al.
Bioactive Materials|December 17, 2025
Designed bone-targeting ROS-responsive nanoplatform for precision glycolysis inhibition in postmenopausal osteoporosisQihang Wu, Jiansen Miao, Yu Chen, et al.
Journal of Cellular Physiology|September 23, 2020
A missense mutation sheds light on a novel structure-function relationship of RANKLHeng Qiu, An Qin, Taksum Cheng, et al.
Frontiers in Pharmacology|February 7, 2022
Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 PathwaysGang Wang, Chao Ma, Kai Chen, et al.
Molecular and Cellular Endocrinology|December 3, 2014
Triptolide inhibits osteoclast formation, bone resorption, RANKL-mediated NF-қB activation and titanium particle-induced osteolysis in a mouse modelJianbin Huang, Lin Zhou, Huafei Wu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 5, 2024
Bone-protective effects of neutralizing angiopoietin-like protein 4 monoclonal antibody in rheumatoid arthritisLiqing Ke, Qifei He, Jing Qu, et al.
Journal of Cellular Physiology|March 1, 2019
Daphnetin attenuates LPS-induced osteolysis and RANKL mediated osteoclastogenesis through suppression of ERK and NFATc1 pathwaysZuoxing Wu, Hailun Wu, Chen Li, et al.
Pharmacological Research|May 27, 2020
Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activationDelong Chen, Zhen Ye, Chao Wang, et al.
Pageof 41